During 2024, drug manufacturers raised prices 2-2.5 times, explaining the alleged high cost of promoting their goods, Yuri Zaslavsky said.
Manufacturers of drugs in Ukraine have not reduced prices for their products after cancellation of marketing agreements, transferring “offense” as if pharmacies. This is thanks to marketing agreements of pharmacies that can offer discounts on drugs and make it more affordable. Citizen’s deputy from the people of the people, a member of the Verkhovna Rada Committee on the Health of the Nation, Medical Care and Medical Insurance by Yuri Zaslavsky on Wednesday, April 2, said in a commentary on UNN commentary.
According to his estimates, a collapse was formed in the pharmaceutical market due to the introduction of new regulation. Despite the ban on the conclusion of marketing agreements between pharmacies and manufacturers, which, in fact, released plants from the need to pay interest in retail, the prices of the drugs didn’t just go down – they continued to grow fast.
According to Zaslavsky, during 2024, manufacturers raised prices 2-2.5 times, explaining the alleged high cost of promoting their goods. And after the introduction of a new regulation of the pharmaceutical market from March 1, marketing agreements between manufacturers and pharmacies are prohibited.
“If you take it fairly, then after the marketing ban, the manufacturers do not have to pay for these services. And they should reduce their prices. Even if this marketing is banned for two months, please, within two months, this amount has been added, that you have invested in the price of drugs, deduct it.
Instead, pharmacies, with no income in the form of marketing agreements, are forced to independently cover their costs.
In addition, the People’s deputy draws attention to the fact that due to the loss of marketing agreements, the state budget entry will decrease, as previous pharmacies pay taxes for such revenues. In addition, Zaslavsky will not exclude that the complete marketing ban will lead to the emergence of shadow schemes.
He emphasized that the state is currently not controlling the sale prices of drug manufacturers, but limiting exclusive margins of shares and pharmacies. This is despite the fact that, according to studies, 72% of the price of drug forms accurately the manufacturer.
According to the People’s deputy, the exit is in return of marketing agreements with transparent taxation and at the same time in a balanced approach to regulating the activities of pharmaceutical networks, shares and manufacturers – as happening in Europe.
According to the Opendatabang service, in 2024 only the revenue of only three largest plants reached nearly 23 billion hryvnias. In particular, the income of pharmaceutical company Darnitsa costs more than 6.8 billion UAH, in pharmacus – 10.7 billion UAH, and the Arterium Corporation – 5.2 billion UAH.
Remember that by the end of February, KYIV police conducted searches on the territory of four manufacturing businesses. The media reported that investigation actions were carried out in offices and facilities of making companies Darnitsa, Arterium and Pharmac.
News from CORRESPONDENT.NET On the telegram and whatsapp. Subscribe to our channels https://t.me/KorresPondentNet and WhatsApp
Source: korrespondent
I’m Liza Grey, an experienced news writer and author at the Buna Times. I specialize in writing about economic issues, with a focus on uncovering stories that have a positive impact on society. With over seven years of experience in the news industry, I am highly knowledgeable about current events and the ways in which they affect our daily lives.